Pluri Launches Regenerative Aesthetics Subsidiary Cellav in Collaboration with Miss Universe Skincare
Pluri Inc. has launched Cellav Health and Aesthetics Ltd., focused on science-based regenerative skincare. The company announced a strategic collaboration with Miss Universe Skincare to co-develop a new line of cell-based skincare products.
The collaboration will feature proprietary active ingredients derived from Pluri’s 3D cell expansion platform, with the first product expected to debut in early 2026. These actives, based on exosome technology, aim to support skin rejuvenation, elasticity, and radiance. The official partnership launch will take place during the 74th Miss Universe pageant events in Thailand.
“At Miss Universe Skincare, we believe that true beauty begins at the cellular level,” said Olivia Quido, President of Miss Universe Skincare and Vice President of Global Partnerships, Miss Universe Organization. “Through our collaboration with Cellav by Pluri, we are proud to introduce the extraordinary benefits of exosome technology—one of the most advanced frontiers in skincare science. Exosomes derived from regenerative biotechnology help boost skin rejuvenation, enhance elasticity, and restore natural luminosity. By integrating these powerful actives into our formulations, we continue our mission to empower every individual to glow with confidence, vitality, and purpose.”
Cellav will be led by Katty Dowery, a pharmaceutical engineer with more than a decade of experience in cell-based and regenerative technologies. The move signals Pluri’s expansion into high-growth wellness markets, aligning with its broader goal of near-term revenue generation and commercial scalability.
“Our partnership with Miss Universe Skincare marks more than just a strategic brand collaboration—It’s a clear step forward in Pluri’s focused strategy to apply our platform where we believe our technology can make the greatest impact,” said Yaky Yanay, Chief Executive Officer and President of Pluri. “By launching Cellav, we are expanding into a high-demand market with a differentiated, science-driven offering—one that aligns with our commitment to near-term revenue generation, scalable innovation, and advancing global wellbeing.”